Resignation of Director

NZX Announcement

1 April 2020

Resignation of Director

Truscreen Limited (“the Company”) announces that prominent New Zealand gynaecologist, Dr. Ron
Jones has retired from the board of the Company as at 31 March 2020. Dr. Jones has also stepped
down from the Company’s Medical Advisory Board (“MAC”). The board of the Company will be
reduced to four directors. The MAC will also be reduced to a committee of two members.

Dr. Jones joined the board as a non-executive director on 19 October 2017 and provided counsel to
the Company on the development of and successful commercialisation of the Company’s Truscreen T2
cervical cancer screening device. He also provided an important link between the board and the MAC
in relation to the MAC’s development of clinical trial protocols and analysis of clinical trial results.

Dr. Jones was an early key contributor of cervical cancer screening trial results from Auckland Hospital
that significantly added to the benchmark datasets on which the Truscreen technology was
developed.

On behalf of the board, the Truscreen team and fellow members of the MAC, we thank Dr. Jones for
his contributions to Truscreen and extend our best wishes for all his future endeavours in his
retirement.



Tony Ho
Chairman

- ENDS -

For more information, visit www.truscreen.com or contact:
TruScreen
Tony Ho
Chairman
tonyho@truscreen.com

About TruScreen:
TruScreen is a Cervical Cancer Screening Device which
offers the latest technology in cervical screening,
providing real-time, accurate detection of pre-
cancerous and cancerous cervical cells to help improve
the health and well-being of women around the world.
TruScreen’s real-time cervical cancer technology
utilises a digital wand which is placed on the surface of
the cervix to measure electrical and optical signals from
the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous
change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing
issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and
the need for supporting laboratory infrastructures. As such, TruScreen’s target market is low-
and middle-income countries where no large-scale cervical cancer screening programs and
infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical
cancer screening device is CE-marked and certified for use throughout Europe and CFDA-
approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen- ultra-
video/